20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid)
Key Takeaways
- CO₂ pneumoperitoneum during laparoscopy should be maintained at an intra-abdominal pressure (IAP) of 12 to 15 mmHg; insufflation increases SVR, MAP, and myocardial wall stress while decreasing venous return, cardiac index, and renal cortical blood flow.
- Cephalad diaphragmatic shift during laparoscopy reduces FRC by 20% to 30%, increases peak airway pressures, and promotes dependent atelectasis; steep Trendelenburg positioning further exacerbates these changes and increases the risk of inadvertent right mainstem endobronchial intubation.
- Pheochromocytoma mandates an inviolable preoperative pharmacologic sequence: complete alpha-adrenergic blockade (Phenoxybenzamine or Doxazosin for 10-14 days) MUST precede beta-adrenergic blockade to prevent unopposed alpha-1 vasoconstriction, catastrophic hypertensive crisis, and acute pulmonary edema.
- Intraoperative pheochromocytoma management features two distinct hemodynamic crises: severe hypertensive surges during tumor manipulation (treated with Sodium Nitroprusside, Nicardipine, Clevidipine, and Magnesium Sulfate) followed by profound refractory vasoplegic shock upon tumor vein ligation (managed with aggressive volume loading, Vasopressin, and Norepinephrine).
- Carcinoid crisis is triggered by tumor manipulation or sympathomimetic administration, releasing massive amounts of serotonin, bradykinin, and kallikrein; definitive management requires high-dose Octreotide (100-500 mcg IV bolus), while sympathomimetics (Ephedrine, Epinephrine) and histamine-releasing drugs are strictly contraindicated.
Last updated: August 2026
20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid)
Advanced intra-abdominal and endocrine tumor procedures present complex hemodynamic, ventilatory, and neurohumoral challenges. Anesthesia providers must anticipate the physiological consequences of laparoscopic CO₂ insufflation, prevent catastrophic hypertensive and vasoplegic crises during pheochromocytoma resection, and effectively manage carcinoid crises with targeted receptor pharmacology.
1. Laparoscopy & CO₂ Pneumoperitoneum Physiology
Laparoscopic surgery utilizes peritoneal insufflation with carbon dioxide ($CO_2$) to create a working space. Carbon dioxide is the preferred gas because it is non-flammable (permitting electrocautery/laser use), highly soluble in blood (rapidly absorbed and expired, minimizing the severity of gas embolism), and cleared efficiently by pulmonary ventilation.
+---------------------------------------------------------------------------------------------------------+
| PHYSIOLOGICAL IMPACT OF CO₂ PNEUMOPERITONEUM |
+-----------------------+--------------------------------------+------------------------------------------+
| Organ System | Physiologic Alteration | Anesthetic Management & Impact |
+-----------------------+--------------------------------------+------------------------------------------+
| **Intra-Abdominal** | • Target working IAP: **12 - 15 mmHg**| • Pressures >15 mmHg severely compromise |
| **Pressure (IAP)** | • Compression of splanchnic/IVC beds | cardiac output and organ perfusion |
+-----------------------+--------------------------------------+------------------------------------------+
| **Systemic Hemodynam-**| • **SVR INCREASES (↑ 30 - 50%)** | • Mechanical aortic compression + release|
| **ics** | • **MAP & Afterload INCREASE** | of vasopressin, renin, catecholamines |
| | • **Cardiac Output DECREASES (↓ 10-30%)**| • IVC compression reduces venous return |
+-----------------------+--------------------------------------+------------------------------------------+
| **Cardiac Conduction**| • Peritoneal stretch triggers | • Treat severe bradycardia/asystole with |
| | **acute vagal reflex (bradycardia)**| immediate desufflation & glycopyrrolate|
+-----------------------+--------------------------------------+------------------------------------------+
| **Renal Function** | • Renal vascular resistance ↑ | • Direct renal vein/parenchymal compress-|
| | • **GFR & Urine Output DECREASE** | ion; transient oliguria is expected |
+-----------------------+--------------------------------------+------------------------------------------+
| **Respiratory Mechan-**| • Diaphragm displaced cephalad | • Peak inspiratory pressures (PIP) ↑ |
| **ics** | • **FRC DECREASES by 20 - 30%** | • Pulmonary compliance ↓; atelectasis |
+-----------------------+--------------------------------------+------------------------------------------+
| **Arterial Blood Gas**| • Continuous systemic CO₂ absorption | • ETCO₂ rises, plateaus in 15-30 min; |
| | • Hypercapnia & respiratory acidosis | requires **20 - 30% ↑ in Minute Vent.**|
+-----------------------+--------------------------------------+------------------------------------------+
[HEMODYNAMIC PROFILE OF IAP ELEVATION]
Hemodynamic Parameter
^
High| SVR / MAP / Afterload (↑↑)
| /---------------------------------
| /
| / Stroke Volume / Cardiac Output (↓↓)
| / /--------------------------------
Low+-------------+---+---------------------------------->
0 10 15 25
Intra-Abdominal Pressure (IAP, mmHg)
Positioning Effects: Trendelenburg vs. Reverse Trendelenburg
- Steep Trendelenburg (Pelvic / Lower GI / Robotic Urology):
- Gravity pushes abdominal viscera cephalad against the diaphragm, further exacerbating FRC reduction, decreasing pulmonary compliance, and increasing peak inspiratory pressures.
- Significantly increases central venous pressure (CVP), intracranial pressure (ICP), and intraocular pressure (IOP), elevating the risk of ischemic optic neuropathy (ION) and cerebral edema.
- Airway Hazard: The carina shifts cephalad as the lungs are compressed, causing the fixed endotracheal tube to migrate deeper into the airway, resulting in unintentional right mainstem endobronchial intubation.
- Reverse Trendelenburg (Upper GI / Bariatric / Cholecystectomy):
- Improves diaphragmatic excursion and FRC, but promotes venous pooling in lower extremities, worsening the reduction in venous return and cardiac output induced by pneumoperitoneum.
Complication: CO₂ Gas Embolism
- Etiology: Inadvertent direct placement of a Veress needle or laparoscopic trocar into a major intra-abdominal vessel (e.g., inferior vena cava, iliac vein, mesenteric vein) during high-flow insufflation.
- Clinical Presentation: Sudden, catastrophic drop in end-tidal CO₂ (due to dead-space ventilation and RVOT vapor lock), acute pulmonary hypertension, cyanosis, severe hypotension, hypoxemia, and a "mill-wheel" murmur.
- Emergency Management:
- Immediately release the pneumoperitoneum (desufflate abdomen).
- Discontinue nitrous oxide and administer 100% FiO₂.
- Place patient in Durant's position (Left Lateral Decubitus with Trendelenburg tilt) to trap the gas bubble in the right ventricular apex away from the pulmonary outflow tract.
- Aspirate gas from a central venous catheter if present.
- Initiate aggressive hemodynamic support and chest compressions if cardiac arrest occurs.
2. Pheochromocytoma: Pathophysiology & Preoperative Optimization
Pheochromocytomas are rare, highly vascular catecholamine-secreting neuroendocrine tumors derived from chromaffin cells of the adrenal medulla (85-90%) or extra-adrenal paraganglia (paragangliomas, 10-15%). They secrete variable ratios of norepinephrine (predominantly), epinephrine, and occasionally dopamine.
+---------------------------------------------------------------------------------------------------------+
| PHEOCHROMOCYTOMA CLINICAL OVERVIEW |
+-----------------------+--------------------------------------+------------------------------------------+
| Diagnostic Domain | Clinical Findings | Key Associations & Confirmatory Tests |
+-----------------------+--------------------------------------+------------------------------------------+
| **Classic Triad** | 1. Paroxysmal / Episodic Headache | • Severe episodic hypertension |
| | 2. Profuse Diaphoresis (Sweating) | • Palpitations, tremulousness, pallor |
| | 3. Tachycardia / Palpitations | • Hyperglycemia (gluconeogenesis/glycog) |
+-----------------------+--------------------------------------+------------------------------------------+
| **Genetic Syndromes** | • MEN 2A & MEN 2B (RET proto-oncogene)| • Von Hippel-Lindau (VHL) disease |
| | • Neurofibromatosis Type 1 (NF1) | • Succinate dehydrogenase (SDH) mutations|
+-----------------------+--------------------------------------+------------------------------------------+
| **Biochemical Tests** | • 24-hr urinary metanephrines/catech | • Fractionated plasma free metanephrines |
| | • Urinary Vanillylmandelic Acid (VMA)| (highest diagnostic sensitivity) |
+-----------------------+--------------------------------------+------------------------------------------+
The Inviolable Rule: Alpha-Blockade BEFORE Beta-Blockade
+-------------------------------------------------------------------------+
| PREOPERATIVE PHARMACOLOGIC TIMELINE |
+-------------------------------------------------------------------------+
| STEP 1: INITIATE ALPHA-ADRENERGIC BLOCKADE (10 - 14 Days Preoperative) |
| • Drug of Choice: **Phenoxybenzamine** (irreversible, non-competitive |
| α₁ and α₂ blocker, 10 mg PO BID, titrated to 40-100 mg/day) or |
| selective α₁ blockers (**Doxazosin**, Prazosin, Terazosin) |
| • Goal: Expand contracted intravascular volume; restore vasodilation |
| • Clinical endpoints: Orthostatic hypotension, nasal congestion |
| |
| STEP 2: INITIATE BETA-ADRENERGIC BLOCKADE (2 - 3 Days Preoperative) |
| • Added ONLY AFTER complete alpha-blockade is established |
| • Indication: Treat reflex tachycardia or tachyarrhythmias |
| • Agents: Metoprolol, Atenolol, Labetalol, Esmolol |
+-------------------------------------------------------------------------+
NCE Fatal Exam Trap — The Unopposed Alpha Catastrophe: NEVER administer a beta-blocker prior to establishing complete alpha-adrenergic blockade. Beta-2 adrenergic receptors in skeletal muscle vascular beds mediate vasodilation. If a non-selective beta-blocker (or any beta-blocker) is given while vascular alpha-1 receptors remain unblocked, two fatal events occur:
- Blockade of vasodilatory $\beta_2$ receptors leaves circulating norepinephrine and epinephrine to act unopposed on vascular $\alpha_1$ receptors, precipitating malignant vasoconstriction and catastrophic hypertensive crisis.
- Blockade of myocardial $\beta_1$ inotropic support prevents the left ventricle from overcoming the massive afterload spike, triggering acute left ventricular failure and flash pulmonary edema.
Roizen Criteria for Preoperative Adequacy
- Blood pressure $< 160/90 \text{ mmHg}$ consistently for at least 24 to 48 hours.
- Orthostatic hypotension present (systolic blood pressure decrease $>10 \text{ mmHg}$ upon standing, but standing systolic BP not $<80 - 90 \text{ mmHg}$).
- Absence of ST-T wave ischemic changes or new arrhythmias on 12-lead EKG for at least 1 to 2 weeks.
- Fewer than 1 premature ventricular contraction (PVC) every 5 minutes.
3. Intraoperative Management of Pheochromocytoma
+---------------------------------------------------------------------------------------------------------+
| INTRAOPERATIVE PHEOCHROMOCYTOMA PHASES |
+-----------------------+--------------------------------------+------------------------------------------+
| Operative Phase | Hemodynamic Threat | Pharmacologic Countermeasures |
+-----------------------+--------------------------------------+------------------------------------------+
| **1. Pre-Induction &**| • Massive catecholamine surge from | • **Arterial Line placed BEFORE induction|
| ** Intubation** | laryngoscopy / intubation stimulus | • Deep plane of anesthesia (Fentanyl, |
| | • Tachycardia & hypertensive spike | Lidocaine, Propofol, Vecuronium) |
+-----------------------+--------------------------------------+------------------------------------------+
| **2. Insufflation &** | • Direct tumor palpation dumps mass- | • **Sodium Nitroprusside** (arterial dil)|
| ** Tumor Manipula-**| ive norepinephrine/epi into blood | • **Nicardipine / Clevidipine** (CCB) |
| ** tion** | • SBP >250 mmHg, tachyarrhythmias | • **Phentolamine** (short-acting α-block)|
| | • Severe ventricular ectopy / VT | • **Esmolol** (short-acting β₁-block) |
| | | • **Magnesium Sulfate** (2-4 g IV bolus) |
+-----------------------+--------------------------------------+------------------------------------------+
| **3. Post-Tumor Vein**| • Sudden withdrawal of catecholamines| • **Aggressive Intravascular Volume** |
| ** Ligation** | • Down-regulated vascular receptors | • **Vasopressin Infusion** (V₁ receptor) |
| | • Residual preop alpha-blockade | • **Norepinephrine / Epinephrine** |
| | • **Profound Vasoplegic Collapse** | • Calcium chloride for inotropic support |
+-----------------------+--------------------------------------+------------------------------------------+
Drug Selection Rules for Pheochromocytoma
- Drugs to AVOID:
- Histamine-releasing agents (Morphine, Meperidine, Atracurium) $\rightarrow$ histamine triggers catecholamine release from chromaffin granules.
- Indirect-acting sympathomimetics (Ephedrine) $\rightarrow$ releases endogenous norepinephrine stores.
- Vagolytics & Arrhythmogenics (Atropine, Pancuronium, Ketamine, Halothane, Desflurane rapid concentration jumps).
- Dopamine antagonists (Metoclopramide, Droperidol) $\rightarrow$ can provoke hypertensive crisis by blocking presynaptic dopamine-mediated inhibition of catecholamine release.
- Magnesium Sulfate in Pheochromocytoma:
- Magnesium acts as a physiological calcium antagonist: it inhibits the exocytosis of catecholamines from adrenal chromaffin granules, reduces vascular smooth muscle responsiveness to catecholamines, and dilates peripheral arterioles without causing reflex tachycardia.
4. Carcinoid Syndrome & Carcinoid Crisis Management
Carcinoid tumors are neuroendocrine neoplasms arising from enterochromaffin (Kulchitsky) cells, most commonly in the gastrointestinal tract (ileum, appendix, rectum) and bronchopulmonary system. They synthesize and secrete serotonin (5-HT), bradykinin, histamine, kallikrein, and prostaglandins.
+-------------------------------------------------------------------------+
| CARCINOID PATHOPHYSIOLOGY & METASTASES |
+-------------------------------------------------------------------------+
| 1. Primary GI Carcinoid: Vasoactive substances drain into portal system |
| → 100% metabolized by hepatic monoamine oxidase (MAO) on first pass |
| → NO systemic carcinoid symptoms occur |
| |
| 2. Hepatic Metastases or Bronchial/Ovarian Carcinoid: |
| → Vasoactive mediators drain DIRECTLY into systemic circulation |
| → Bypasses hepatic metabolism → **CARCINOID SYNDROME MANIFESTS** |
+-------------------------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------+
| CARCINOID SYNDROME CLINICAL FEATURES |
+-----------------------+--------------------------------------+------------------------------------------+
| Clinical Manifestation| Biochemical Mediator | Pathophysiology & Exam Findings |
+-----------------------+--------------------------------------+------------------------------------------+
| **Cutaneous Flushing**| Bradykinin, Histamine, Serotonin | • Episodic bright red/violaceous erythema|
| | | of the face, neck, and upper torso |
+-----------------------+--------------------------------------+------------------------------------------+
| **Secretory Diarrhea**| Serotonin (5-HT) | • Intractable watery diarrhea, cramps |
+-----------------------+--------------------------------------+------------------------------------------+
| **Bronchospasm** | Serotonin, Bradykinin, Histamine | • Severe wheezing, dyspnea, high PIP |
+-----------------------+--------------------------------------+------------------------------------------+
| **Right-Sided Heart** | Serotonin (fibroblast stimulation) | • **Tricuspid Regurgitation** |
| **Disease (Hedinger)**| | • **Pulmonary Valve Stenosis** |
| | | • **Left-sided valves SPARED** (pulmonary|
| | | endothelial MAO degrades serotonin) |
+-----------------------+--------------------------------------+------------------------------------------+
| **Diagnostic Marker** | **24-hour urinary 5-HIAA** | • End product of serotonin metabolism |
+-----------------------+--------------------------------------+------------------------------------------+
Carcinoid Crisis: Emergency Rescue Pharmacology
Carcinoid crisis is a life-threatening oncologic emergency precipitated by tumor manipulation, anesthesia induction, hypothermia, hypoxia, or catecholamine administration. It manifests as refractory, profound hypotension (or occasionally severe hypertension), intense flushing, intractable bronchospasm, and ventricular arrhythmias.
+---------------------------------------------------------------------------------------------------------+
| CARCINOID CRISIS MANAGEMENT PROTOCOL |
+-----------------------+--------------------------------------+------------------------------------------+
| Strategy | Drug & Dosage | Mechanism & Clinical Rationale |
+-----------------------+--------------------------------------+------------------------------------------+
| **FIRST-LINE DRUG OF**| **Octreotide (Sandostatin)** | • Synthetic somatostatin analog that spe-|
| **CHOICE (RESCUE)** | **100 - 500 mcg IV Bolus** | cifically inhibits exocytosis of sero- |
| | Followed by **50 - 200 mcg/hr** inf. | tonin, bradykinin, and gut peptides |
+-----------------------+--------------------------------------+------------------------------------------+
| **Vasopressor of** | **Vasopressin** or **Phenylephrine** | • Direct V₁ / α₁ vasoconstriction |
| **Choice (if needed)**| | • Does NOT stimulate tumor release |
+-----------------------+--------------------------------------+------------------------------------------+
| **CONTRAINDICATED** | **Ephedrine, Epinephrine, Isoproter-**| • **STRICTLY PROHIBITED:** Beta-agonism |
| **DRUGS** | **enol, Dopamine, Norepinephrine** | stimulates tumor adenylate cyclase, |
| | | triggering massive paradoxical release |
| | | of serotonin/bradykinin (worsens shock)|
+-----------------------+--------------------------------------+------------------------------------------+
| **Avoid Histamine** | Morphine, Meperidine, Atracurium | • Histamine triggers mediator cascade |
| **Releasers** | | |
+-----------------------+--------------------------------------+------------------------------------------+
Loading diagram...
Test Your Knowledge
A 45-year-old female with a newly diagnosed right adrenal pheochromocytoma is scheduled for laparoscopic adrenalectomy. Her resting heart rate is 112 bpm with frequent premature ventricular contractions, and blood pressure is 188/110 mmHg. Why must alpha-adrenergic blockade be instituted prior to initiating beta-adrenergic blockade?
A
B
C
D
Test Your Knowledge
During laparoscopic cholecystectomy with a CO₂ pneumoperitoneum at an intra-abdominal pressure of 15 mmHg, what physiological changes in systemic vascular resistance (SVR), cardiac output (CO), and functional residual capacity (FRC) are expected?
A
B
C
D
Test Your Knowledge
A 62-year-old male with metastatic small-bowel carcinoid tumor undergoes liver resection. Following surgical traction on the hepatic tumor, the patient develops severe cutaneous erythema across his chest, intractable bronchospasm with peak airway pressures rising to 48 cmH₂O, and arterial blood pressure plunging to 60/32 mmHg. Which intervention is the definitive first-line rescue therapy, and which drug is strictly contraindicated?
A
B
C
D
Test Your Knowledge
Immediately following the ligation of the adrenal vein during a laparoscopic pheochromocytoma resection, the patient's arterial blood pressure suddenly falls from 165/95 mmHg to 62/34 mmHg. What is the primary underlying etiology of this hypotension, and what is the optimal management strategy?
A
B
C
D